Combining the prognosis analysis, RT and chemotherapy sensitivity analysis, and tumor infiltrated immune cell subsets analysis, we concluded that patients with higher expression of PTPRN and RIM-BP2 were resistant to RT and chemotherapy, potentially due to poor tumor microenvironment; therefore, their prognosis was very poor. The gene discussed is PTPRN; the disease is neoplasm.